Sanofi, a French pharmaceutical company, is recommended as a promising dividend stock with a 5.6% yield that approaches 11% when including stock buybacks. The company is growing well with its flagship drug Dupixent showing 31% year-over-year sales growth, and the stock trades at an attractive valuation with a forward P/E ratio of 9, well below its five-year average.
Axe note: Sanofi offers a rare global dividend yield near 6%, boosted by solid sales growth in immunology and attractive valuation.